Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 795-779

  Murray, Henry W ^a,b   Delph Etienne, Sharmaine ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Box 130 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GRANULOMA; IMMUNE DEFICIENCY; IN VITRO STUDY; INTRACELLULAR KILLING; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGE ACTIVATION; MICE; PHOSPHORYLCHOLINE; T-LYMPHOCYTES;

EID: 0034048702     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315268     Document Type: Article

References (18)

1. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36:1630-4.
2. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllsophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996; 38:1041-7.
3. Le Fichoux Y, Rousseau D, Ferrua B, et al. Short and long term efficacy of hexadecylphosphocholine in established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 1998; 42:654-8.
4. Sundar S, Gupta LB, Makharia MK, et al. Oral treatment with miltefosine for visceral leishmaniasis. Ann Trop Med Parasitol 1999; 93:589-97.
5. Hochhuth CH, Vehmeyer K, Eibl H, Unger C. Hexadecylphosphocholine induces interferon-γ secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol 1992; 141:161-8.
6. Zeisig R, Rudolf M, Eue I, Arndt D. Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J Cancer Res Clin Oncol 1995; 121:69-75.
7. Eue I, Zeisig R, Arndt D. Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor-α by U937 cells. J Cancer Res Clin Oncol 1995; 121:350-6.
8. Beckers T, Voegeli R, Hilgard P. Molecular and cellular effects of hexadecylphosphocholine (miltefosine) in human myeloid leukaemic cell lines. Eur J Cancer 1994; 30A:2143-50.
9. Murray HW, Nathan CK. Macrophage microbicidal mechanisms in vivo: reactive nitrogen vs. oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 1999; 189:741-6.
10. Shiloh MU, Nathan CF. Antimicrobial mechanisms of macrophages. In: Gordon S, ed. Phagocytosis and pathogens. Greenwich, CT: JAI Press, 1999:407-39.
11. Murray HW. Granulomatous inflammation: host antimicrobial defense in the tissues in visceral leishmaniasis. In: Gallin JI, Snyderman R, Fearon DT, Haynes BF, Nathan CF, eds. Inflammation: basic principles and clinical correlates. Philadelphia: Lippincott-Raven, 1999:977-94.
12. r congenic mouse strains. Infect Immun 1991; 59:3935-44.
13. Murray HW, Hariprashad J, Fichtl R. Treatment of experimental visceral leishmaniasis in a T cell deficient host: response to amphotericin B and pentamidine. Antimicrob Agents Chemother 1993; 37:1504-5.
14. Murray HW, Berman JD, Wright SD. Immunochemotherapy for intracellular Leishmania donovani infection: interferon-γ plus pentavalent antimony. J Infect Dis 1988; 157:973-9.
15. Murray HW, Delph-Etienne S. Role of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemtherapy in experimental visceral leishmaniasis. Infect Immun 2000; 68:288-92.
16. Murray HW. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDs 1999; 13:459-65.
17. Ibrahim ME, Hag-Ali M, El-Hassan AM, Theander TG, Kharazim A. Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing. Parasitol Res 1994; 80:569-74.
18. Zhou P, Sieve MC, Tewari RP, Seder RA. Interleukin 12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum. Infect Immun 1997; 65:936-42.